How to buy Catabasis Pharmaceuticals stock

Catabasis Pharmaceuticals Inc is a biotechnology business based in the US. Catabasis Pharmaceuticals shares (CATB) are listed on the NASDAQ and all prices are listed in US Dollars. Catabasis Pharmaceuticals employs 20 staff and has a market cap (total outstanding shares value) of 0.00.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Catabasis Pharmaceuticals stock price (NASDAQ: CATB)

Use our graph to track the performance of CATB stocks over time.

Catabasis Pharmaceuticals shares at a glance

• Key figures

Information last updated 2022-01-09.

52-week range	$6.31 - $12.66
50-day moving average more info button	$8.23
200-day moving average more info button	$3.74
Wall St. target price	$23.00
PE ratio more info button	N/A
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$-54.39

Buy Catabasis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Catabasis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catabasis Pharmaceuticals price performance over time

Historical closes compared with the close of $N/A from 2021-12-08

1 week (2022-06-21)	N/A
1 month (2022-05-29)	N/A
3 months (2022-03-29)	N/A
6 months (2021-12-29)	N/A

1 year (2021-07-02)	-100.00%
2 years (2020-07-02)	-100.00%
3 years (2019-07-02)	-100.00%
5 years (2017-06-30)	-100.00%

Catabasis Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-20.32%
Return on equity TTM	-210.26%
Profit margin	0%
Book value	$2.90
Market capitalisation more info button	$109.5 million

TTM: trailing 12 months

Catabasis Pharmaceuticals share dividends

We're not expecting Catabasis Pharmaceuticals to pay a dividend over the next 12 months.

Have Catabasis Pharmaceuticals's shares ever split?

Catabasis Pharmaceuticals's shares were split on a 1:6 basis on 19 August 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catabasis Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Catabasis Pharmaceuticals shares which in turn could have impacted Catabasis Pharmaceuticals's share price.

Catabasis Pharmaceuticals share price volatility

Over the last 12 months, Catabasis Pharmaceuticals's shares have ranged in value from as little as $6.31 up to $12.66. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catabasis Pharmaceuticals's is 1.6632. This would suggest that Catabasis Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catabasis Pharmaceuticals overview

Catabasis Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts. .

Frequently asked questions

What percentage of Catabasis Pharmaceuticals is owned by insiders or institutions?
Currently 0.034% of Catabasis Pharmaceuticals shares are held by insiders and 55.084% by institutions. How many people work for Catabasis Pharmaceuticals?
Latest data suggests 20 work at Catabasis Pharmaceuticals. When does the fiscal year end for Catabasis Pharmaceuticals?
Catabasis Pharmaceuticals's fiscal year ends in December. Where is Catabasis Pharmaceuticals based?
Catabasis Pharmaceuticals's address is: 100 High Street, Boston, MA, United States, 02110 What is Catabasis Pharmaceuticals's ISIN number?
Catabasis Pharmaceuticals's international securities identification number is: US04635X1028 What is Catabasis Pharmaceuticals's CUSIP number?
Catabasis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 14875P107